JPWO2023033129A1 - - Google Patents

Info

Publication number
JPWO2023033129A1
JPWO2023033129A1 JP2022571749A JP2022571749A JPWO2023033129A1 JP WO2023033129 A1 JPWO2023033129 A1 JP WO2023033129A1 JP 2022571749 A JP2022571749 A JP 2022571749A JP 2022571749 A JP2022571749 A JP 2022571749A JP WO2023033129 A1 JPWO2023033129 A1 JP WO2023033129A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022571749A
Other languages
Japanese (ja)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2023033129A1 publication Critical patent/JPWO2023033129A1/ja
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2022571749A 2021-09-03 2022-09-02 Pending JPWO2023033129A1 (US07585860-20090908-C00150.png)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021143764 2021-09-03
PCT/JP2022/033055 WO2023033129A1 (ja) 2021-09-03 2022-09-02 癌の治療及び/又は予防用医薬組成物

Publications (1)

Publication Number Publication Date
JPWO2023033129A1 true JPWO2023033129A1 (US07585860-20090908-C00150.png) 2023-03-09

Family

ID=85412442

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022571749A Pending JPWO2023033129A1 (US07585860-20090908-C00150.png) 2021-09-03 2022-09-02

Country Status (5)

Country Link
JP (1) JPWO2023033129A1 (US07585860-20090908-C00150.png)
KR (1) KR20240051956A (US07585860-20090908-C00150.png)
AU (1) AU2022338463A1 (US07585860-20090908-C00150.png)
CA (1) CA3230737A1 (US07585860-20090908-C00150.png)
WO (1) WO2023033129A1 (US07585860-20090908-C00150.png)

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4486414A (en) 1983-03-21 1984-12-04 Arizona Board Of Reagents Dolastatins A and B cell growth inhibitory substances
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
FR2613935B1 (fr) 1987-04-15 1989-12-01 Roussel Uclaf Association renfermant a titre de principes actifs, un analgesique central et la forskoline
US4816444A (en) 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
US5076973A (en) 1988-10-24 1991-12-31 Arizona Board Of Regents Synthesis of dolastatin 3
US4978744A (en) 1989-01-27 1990-12-18 Arizona Board Of Regents Synthesis of dolastatin 10
US4986988A (en) 1989-05-18 1991-01-22 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13
US5138036A (en) 1989-11-13 1992-08-11 Arizona Board Of Regents Acting On Behalf Of Arizona State University Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14
JPH0688488B2 (ja) 1990-10-23 1994-11-09 豊治 藤本 ペルチェ電子素子型の可搬式エアコン及び換気性衣服
EP0598129B1 (en) 1991-08-09 2000-03-22 Teikoku Hormone Mfg. Co., Ltd. Novel tetrapeptide derivative
CA2081406C (en) 1991-12-23 1997-09-16 Chinmoy Bhusan Bose Method and apparatus for connected and degraded text recognition
CZ292612B6 (cs) 1992-05-20 2003-11-12 Abbott Gmbh & Co. Kg Peptid s protirakovinnou aktivitou, jeho použití a farmaceutický prostředek s obsahem takového peptidu
US5831002A (en) 1992-05-20 1998-11-03 Basf Aktiengesellschaft Antitumor peptides
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US6034065A (en) 1992-12-03 2000-03-07 Arizona Board Of Regents Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10
JPH06172397A (ja) 1992-12-11 1994-06-21 Nippon Kayaku Co Ltd 新規物質ドラスタチンc及びその用途
AU679479B2 (en) 1992-12-16 1997-07-03 Basf Aktiengesellschaft Dolostatin analog
US5410024A (en) 1993-01-21 1995-04-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
ATE282630T1 (de) 1993-10-01 2004-12-15 Teikoku Hormone Mfg Co Ltd Dolastatin-derivate
WO1996002576A1 (fr) 1994-07-13 1996-02-01 Chugai Seiyaku Kabushiki Kaisha Anticorps humain reconstitue contre l'interleukine-8 humaine
US5530097A (en) 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides
US5521284A (en) 1994-08-01 1996-05-28 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides and esters
US5504191A (en) 1994-08-01 1996-04-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide methyl esters
US5840699A (en) 1995-04-21 1998-11-24 Teikoku Hormone Mfg. Co. Ltd. Peptide derivatives
DE19527575A1 (de) 1995-07-28 1997-01-30 Basf Ag Verfahren zur Herstellung von peptidischer Wirkstoffe
JPH0977791A (ja) 1995-09-08 1997-03-25 Nippon Kayaku Co Ltd ペプチド誘導体及びその用途
US5816444A (en) 1995-10-23 1998-10-06 Calico Light Weapon Systems Rotor and ratchet assembly
US5807984A (en) 1995-11-09 1998-09-15 Basf Aktienegesellschaft Oligopeptides, the preparation and use thereof
US5939527A (en) 1996-07-30 1999-08-17 Basf Aktiengesellschaft Tetrapeptides as antitumor agents
US5741892A (en) 1996-07-30 1998-04-21 Basf Aktiengesellschaft Pentapeptides as antitumor agents
US6239104B1 (en) 1997-02-25 2001-05-29 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear and cyclo-depsipeptides dolastatin 16, dolastatin 17, and dolastatin 18
US5965537A (en) 1997-03-10 1999-10-12 Basf Aktiengesellschaft Dolastatin 15 derivatives with carbonyl and heterocyclic functionalities at the C-terminus
US6103698A (en) 1997-03-13 2000-08-15 Basf Aktiengesellschaft Dolastatin-15 derivatives in combination with taxanes
US6143721A (en) 1997-07-18 2000-11-07 Basf Aktiengesellschaft Dolastatin 15 derivatives
EP1049481B1 (en) 1997-09-24 2005-04-20 Arizona Board Of Regents Synthetic antineoplastic agents derived from dolastatin 15 and methods of making same
US6677436B1 (en) 1998-04-03 2004-01-13 Chugai Seiyaku Kabushiki Kaisha Humanized antibody against human tissue factor (TF) and process of production of the humanized antibody
WO1999054342A1 (en) 1998-04-20 1999-10-28 Pablo Umana Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US5985837A (en) 1998-07-08 1999-11-16 Basf Aktiengesellschaft Dolastatin 15 derivatives
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
ES2568899T3 (es) 1999-04-09 2016-05-05 Kyowa Hakko Kirin Co., Ltd. Procedimiento para controlar la actividad de una molécula inmunofuncional
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US7256257B2 (en) 2001-04-30 2007-08-14 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US6737409B2 (en) 2001-07-19 2004-05-18 Hoffmann-La Roche Inc. Dolastatin 10 derivatives
PT1545613E (pt) 2002-07-31 2011-09-27 Seattle Genetics Inc Conjugados de auristatina e sua utilização para tratamento do cancro, de uma doença autoimune ou de uma doença infecciosa
US7355008B2 (en) 2003-01-09 2008-04-08 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
SG10201701737XA (en) 2003-11-06 2017-04-27 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
DE10359795A1 (de) 2003-12-19 2005-07-21 Bayer Technology Services Gmbh Strangverdampfervorrichtung
EP1817336B1 (en) 2004-11-12 2019-01-09 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the n terminus
EP1817341A2 (en) 2004-11-29 2007-08-15 Seattle Genetics, Inc. Engineered antibodies and immunoconjugates
BRPI0519023A2 (pt) 2004-12-13 2008-12-23 Hoffmann La Roche composiÇço farmacÊutica contendo pelo menos um derivado de dolastatina 10
JP5171621B2 (ja) 2005-07-07 2013-03-27 シアトル ジェネティックス, インコーポレイテッド フェニルアラニン側鎖修飾をc末端に有するモノメチルバリン化合物
PT2322221E (pt) 2008-08-05 2014-09-19 Toray Industries Composição farmacêutica para tratamento e prevenção de cancro
US20120213705A1 (en) 2009-06-22 2012-08-23 Medimmune, Llc ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION
CA2773240C (en) 2009-09-22 2015-11-10 Volker Sandig Process for producing molecules containing specialized glycan structures
JP5845899B2 (ja) 2010-02-04 2016-01-20 東レ株式会社 癌の治療及び/又は予防用医薬組成物
PT2532743E (pt) 2010-02-04 2015-08-04 Toray Industries Composição farmacêutica para o tratamento e/ou a prevenção de cancro
MX2012008991A (es) 2010-02-04 2012-09-07 Toray Industries Medicamento para tratar y/o prevenir el cancer.
ES2583777T3 (es) 2010-02-04 2016-09-22 Toray Industries, Inc. Composición farmacéutica que comprende anticuerpos anti CAPRIN-1 para el tratamiento y/o la prevención del cáncer
DK2532366T3 (da) 2010-02-04 2017-01-02 Toray Industries Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer
EP2532365B1 (en) 2010-02-04 2016-05-04 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
BR112012024489A2 (pt) 2010-03-29 2016-05-31 Zymeworks Inc anticorpos com função efetora suprimida ou aumentada
EP2579887B1 (de) 2010-06-10 2014-11-12 Seattle Genetics, Inc. Neue auristatin-derivate und ihre verwendung
US9029406B2 (en) 2011-03-16 2015-05-12 Seattle Genetics, Inc N-carboxyalkylauristatins and use thereof
EP2699268A2 (de) 2011-04-21 2014-02-26 Seattle Genetics, Inc. Neue binder-wirkstoff konjugate (adcs) und ihre verwendung
WO2012148943A1 (en) 2011-04-25 2012-11-01 Arizona Board Of Regents, For And On Behalf Of, Arizona State University Crystal structures of dolastatin 16, dolamethylleuine and dolaphenvaline, and methods for preparing dolamethylleuine and dolaphenvaline
CA2837167A1 (en) 2011-05-27 2012-12-06 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
EP3470413A3 (en) 2011-05-27 2019-08-07 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
JP6003650B2 (ja) 2011-08-04 2016-10-05 東レ株式会社 膵臓癌の治療及び/又は予防用医薬組成物
EP2740798B1 (en) 2011-08-04 2016-12-07 Toray Industries, Inc. Cancer treatment and/or prevention drug composition
PT3351630T (pt) 2011-08-04 2019-12-30 Toray Industries Composição farmacêutica compreendendo anticorpos anti caprin-1 para tratar e/ou prevenir o cancro
JP6065591B2 (ja) 2011-08-04 2017-01-25 東レ株式会社 癌の治療及び/又は予防用医薬組成物
KR101968498B1 (ko) 2011-08-04 2019-04-12 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
KR101980557B1 (ko) 2011-08-04 2019-05-21 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
EP2764351B1 (en) 2011-09-29 2018-11-07 Seattle Genetics, Inc. Intact mass determination of protein conjugated agent compounds
RU2633505C2 (ru) 2012-02-21 2017-10-12 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики рака
AU2013223137B2 (en) 2012-02-21 2017-10-19 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
MX360208B (es) 2012-02-21 2018-10-24 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
CA2864869C (en) 2012-02-21 2021-10-19 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
PL2832365T3 (pl) 2012-03-30 2018-04-30 Toray Industries, Inc. Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi wątroby
JP6107655B2 (ja) 2012-03-30 2017-04-05 東レ株式会社 胆嚢癌の治療及び/又は予防用医薬組成物
CA3131619A1 (en) 2012-05-15 2013-11-21 Seagen Inc. Self-stabilizing linker conjugates
CN112587671A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
JP6089108B2 (ja) 2012-09-20 2017-03-01 セルトリオン, インク. ドラスタチン10誘導体、その製造方法およびそれを含む抗癌剤組成物
FR3005051A1 (fr) 2013-04-25 2014-10-31 Pf Medicament Derives de la dolastatine 10 et d'auristatines
JP6447130B2 (ja) 2013-08-09 2019-01-09 東レ株式会社 癌の治療及び/又は予防用医薬組成物
MX2021008464A (es) 2013-10-15 2023-03-03 Seattle Genetics Inc Farmaco-enlazadores modificados con polietilenglicol para la farmacocinetica mejorada de conjugados de ligando-farmaco.
IL290330B2 (en) 2013-12-19 2023-09-01 Seagen Inc Methylene carbamate binders for use with drug-targeting conjugates
EP3100731A4 (en) * 2014-01-29 2017-12-20 Shanghai Hengrui Pharmaceutical Co., Ltd. Ligand-cytotoxicity drug conjugate, preparation method therefor, and uses thereof
KR102647074B1 (ko) 2014-02-17 2024-03-14 씨젠 인크. 친수성 항체-약물 컨쥬게이트
CN106279352B (zh) 2015-05-29 2020-05-22 上海新理念生物医药科技有限公司 海兔毒素10的衍生物及其应用
KR102626498B1 (ko) 2016-03-25 2024-01-19 씨젠 인크. 페길화된 약물-링커 및 그의 중간체의 제조를 위한 공정
CN108779146B (zh) 2016-03-29 2022-03-18 东丽株式会社 肽衍生物及其用途
MX2019001302A (es) 2016-08-09 2019-06-12 Seattle Genetics Inc Conjugados de farmaco con enlazadores autoestabilizantes que tienen propiedades fisioquimicas mejoradas.
BR112019008335A2 (pt) * 2016-10-28 2020-01-28 Toray Industries conjugado de um anticorpo, composição farmacêutica e método para o tratamento e/ou a prevenção de um câncer
JP7244987B2 (ja) 2016-12-14 2023-03-23 シージェン インコーポレイテッド 多剤抗体薬物コンジュゲート
CN110352074A (zh) 2017-02-28 2019-10-18 西雅图遗传学公司 用于偶联的半胱氨酸突变抗体
AU2019225845A1 (en) 2018-02-20 2020-09-24 Seagen Inc. Hydrophobic Auristatin F compounds and conjugates thereof
CN109796522B (zh) 2019-02-18 2021-09-21 清远中大创新药物研究中心 海兔毒素10环肽衍生物及其制备方法和应用
EP4051691A4 (en) 2019-10-28 2023-11-08 Ariel Scientific Innovations Ltd. DOLASTATIN 10 ANALOG
CA3170633A1 (en) 2020-03-09 2021-09-16 David Goeddel Efficient preparation of dolastatin and auristatin analogs through a common intermediate

Also Published As

Publication number Publication date
KR20240051956A (ko) 2024-04-22
CA3230737A1 (en) 2023-03-09
AU2022338463A1 (en) 2024-03-21
WO2023033129A1 (ja) 2023-03-09

Similar Documents

Publication Publication Date Title
BR112023005462A2 (US07585860-20090908-C00150.png)
BR112023012656A2 (US07585860-20090908-C00150.png)
BR112021014123A2 (US07585860-20090908-C00150.png)
BR112022024743A2 (US07585860-20090908-C00150.png)
BR102021018859A2 (US07585860-20090908-C00150.png)
BR102021015500A2 (US07585860-20090908-C00150.png)
BR112022009896A2 (US07585860-20090908-C00150.png)
BR102021007058A2 (US07585860-20090908-C00150.png)
BR102020022030A2 (US07585860-20090908-C00150.png)
JPWO2023033129A1 (US07585860-20090908-C00150.png)
BR112023011738A2 (US07585860-20090908-C00150.png)
BR112023016292A2 (US07585860-20090908-C00150.png)
BR112023004146A2 (US07585860-20090908-C00150.png)
BR112023011610A2 (US07585860-20090908-C00150.png)
BR112023011539A2 (US07585860-20090908-C00150.png)
BR112023008976A2 (US07585860-20090908-C00150.png)
BR112023009656A2 (US07585860-20090908-C00150.png)
BR112023006729A2 (US07585860-20090908-C00150.png)
BR102021020147A2 (US07585860-20090908-C00150.png)
BR102021018926A2 (US07585860-20090908-C00150.png)
BR102021018167A2 (US07585860-20090908-C00150.png)
BR102021017576A2 (US07585860-20090908-C00150.png)
BR102021016837A2 (US07585860-20090908-C00150.png)
BR102021016551A2 (US07585860-20090908-C00150.png)
BR102021016375A2 (US07585860-20090908-C00150.png)

Legal Events

Date Code Title Description
RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20240213